Morphologically ‘invisible’ proinsulin – secreting adenoma detected by Ga‐68 Exendin‐4 (<scp>GLP</scp>‐1 Receptor) positron emission tomography/<scp>CT</scp>

Werner, Christoph; Lupp, Amelie; Drescher, Robert; Freesmeyer, Martin; Mireskandari, Masoud; Stoykow, C.; Bauschke, Astrid; Müller, Ulrich A.

doi:10.1111/1754-9485.12704

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient experienced complete postoperative recovery. 68 Ga-DOTA-exendin PET/CT was the only method that could visualize the pancreatic lesion and thus facilitate curative surgical treatment 154, 155. Detection of an insulinoma lesion using 68 Ga-DOTA-exendin PET/CT enabled subsequent ultrasound-guided ethanol ablation and monitoring of the tumor response to the treatment 156.…”

Section: Clinical Accomplishmentsmentioning

confidence: 99%

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Velikyan

Eriksson

2020

Theranostics

View full text Add to dashboard Cite

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.

show abstract

Section: Clinical Accomplishmentsmentioning

confidence: 99%

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Velikyan

Eriksson

2020

Theranostics

View full text Add to dashboard Cite

show abstract

Case 23-2018: A Man with Episodes of Confusion and Hypoglycemia

Wexler

Pierce

2018

N Engl J Med

View full text Add to dashboard Cite

Exendin‐4‐based imaging in insulinoma localization: Systematic review and meta‐analysis

Shah

Garg

Majmundar

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

Background and context: Glucagon-like peptide-1 receptor (GLP-1 R) based imaging has shown higher sensitivity for insulinoma localization as compared to other anatomic/functional imaging. Methodology:We reviewed the published English literature for GLP-1 R targeted imaging in insulinoma in PubMed until August 2020 in accordance with PRISMA guidelines using the MeSH terms "((Exendin-4 PET/CT) OR (Exendin-4 SPECT/CT) OR (GLP-1 R imaging)) AND (Insulinoma)". An individual patient data-metanalysis (IPD-MA) was performed, and performance parameters were calculated for the histopathological diagnosis of insulinoma.Main outcome measures: True-positive (TP), false-positive (FP), false-negative (FN), true-negative (TN), sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) for insulinoma localization.Results: A total of 179 cases (316 lesions) from 16 publications were included for IPD-MA. For insulinoma localization, exendin-4-PET/CT (Sn & PPV: 94%) performed better than exendin-4-SPECT/CT (Sn: 63%, PPV: 94%). The Sn was lower in malignant insulinoma cases whereas the Sp was higher in cases with MEN-1 syndrome. With exendin-4-based imaging, FP uptakes in Brunner's gland, normal pancreas, and other β-cell pathologies and FN results in pancreatic tail lesions and malignancy were seen in a few patients. TN results suggested the correct diagnosis of other endogenous hyperinsulinemic hypoglycaemia (EHH) subtypes. Conclusion:For insulinoma localization, exendin-4 PET/CT should be preferred over exendin-4 SPECT/CT because of higher sensitivity and specificity. FP uptakes in Brunner's gland, normal pancreas, and other β-cell pathologies and FN results in tail lesions, and malignant insulinomas are limitations. Higher specificity for insulinoma localization is particularly useful in patients with MEN-1 syndrome.

show abstract

Morphologically ‘invisible’ proinsulin – secreting adenoma detected by Ga‐68 Exendin‐4 (GLP‐1 Receptor) positron emission tomography/CT

Cited by 3 publications

References 17 publications

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

Case 23-2018: A Man with Episodes of Confusion and Hypoglycemia

Exendin‐4‐based imaging in insulinoma localization: Systematic review and meta‐analysis

Contact Info

Product

Resources

About